Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment

George E Fragoulis, Christina Liava, Dimitrios Daoussis, Euangelos Akriviadis, Alexandros Garyfallos, Theodoros Dimitroulas

ORCID number: George E Fragoulis (0000-0003-4932-7023); Christina Liava (orcid.org/0000-0001-9523-5694); Dimitrios Daoussis (0000-0001-8027-3635); Evangelos Akriviadis (0000-0002-7906-6445); Alexandros Garyfallos (0000-0001-7289-1293); Theodoros Dimitroulas (0000-0002-0364-1642).

Author contributions: Fragoulis GE reviewed the literature, drafted the manuscript, designed the structure of the manuscript; Liava C reviewed the literature, drafted the manuscript; Daoussis D drafted the manuscript, critically revised the manuscript; Akriviadis E drafted the manuscript, critically revised the manuscript; Garyfallos A drafted the manuscript, critically revised the manuscript; Dimitroulas T drafted the manuscript, reviewed the literature, critically revised the manuscript, designed the structure of the manuscript.

Conflict-of-interest statement: We declare no conflict of interest.

Open-Access: This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

Abstract

Spondyloarthropathies (SpA) include many different forms of inflammatory arthritis and can affect the spine (axial SpA) and/or peripheral joints (peripheral SpA) with Ankylosing spondylitis (AS) being the prototype of the former. Extra-articular manifestations, like uveitis, psoriasis and inflammatory bowel disease (IBD) are frequently observed in the setting of SpA and are, in fact, part of the SpA classification criteria. Bowel involvement seems to be the most common of these manifestations. Clinically evident IBD is observed in 6%-14% of AS patients, which is significantly more frequent compared to the general population. Besides, it seems that silent microscopic gut inflammation, is evident in around 60% in AS patients. Interestingly, occurrence of IBD has been associated with AS disease activity. For peripheral SpA, two different forms have been proposed with diverse characteristics. Of note, SpA (axial or peripheral) is more commonly observed in Crohn’s disease than in ulcerative colitis. The common pathogenetic mechanisms that explain the link between IBD and SpA are still ill-defined. The role of dysregulated microbiome along with migration of T lymphocytes and other cells from gut to the joint (“gut-joint” axis) has been recognized, in the context of a genetic background including associations with alleles inside or outside the human leukocyte antigen system. Various therapeutic modalities are available with monoclonal antibodies against tumour necrosis factor...
factor, interleukin-23 and interleukin-17, being the most effective. Both gastroenterologists and rheumatologists should be alert to identify the coexistence of these conditions and ideally follow-up these patients in combined clinics.

**Key words:** Spondyloarthropathies; Axial spondyloarthropathies; Peripheral spondyloarthropathies; Ankylosing spondylitis; Inflammatory bowel disease

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Spondyloarthropathies (SpA) are subdivided to axial and peripheral SpA with ankylosing spondylitis (AS) being the prototype disease of the former. They have many extra-articular manifestations the most common of which is bowel involvement. Inflammatory bowel disease (IBD) (silent or clinically evident) occurs much more frequently in AS compared to the general population and associates with AS disease activity. Both axial and peripheral SpA occur more frequently in Crohn’s disease than ulcerative colitis. Pathogenetic mechanisms that have been proposed to explain the link between SpA and IBD include dysregulated microbiome and migration of T lymphocytes and other cells from gut to the joint.

Citation: Fragoulis GE, Liava C, Daoussis D, Akriviadis E, Garyfallos A, Dimitroulas T. Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment. *World J Gastroenterol* 2019; 25(18): 2162-2176

URL: [https://www.wjgnet.com/1007-9327/full/v25/i18/2162.htm](https://www.wjgnet.com/1007-9327/full/v25/i18/2162.htm)

DOI: [https://dx.doi.org/10.3748/wjg.v25.i18.2162](https://dx.doi.org/10.3748/wjg.v25.i18.2162)

**INTRODUCTION**

Under the term spondyloarthropathy (SpA) are classified many inflammatory arthropathies with similar clinical and imaging features. However, diagnostic laboratory or pathological findings with high specificity are lacking. SpA affects mainly the spine, but symptomatology from the peripheral joints as well as from entheses and other tissues might occur. SpA include: psoriatic arthritis (PsA), peripheral SpA, enteropathic [also known as inflammatory bowel disease (IBD)-related] arthritis, reactive arthritis, undifferentiated spondyloarthropathy and axial spondyloarthropathy (axSpA) which includes non-radiographic axial spondyloarthropathy (nraxSpA), and Ankylosing spondylitis (AS)\(^\text{1}\). The latter is considered the prototype of these diseases\(^\text{1}\). Enthesitis (inflammation of the entheses which are the insertions of the ligaments and tendons into the bone) is thought to be one of the key manifestations in SpA, helping to distinguish from other inflammatory arthropathies\(^\text{1}\). Apart from the skeletal disease, extra-articular manifestations like uveitis, psoriasis and inflammatory bowel disease often occur\(^\text{1}\), offering significant help in the diagnosis of these diseases and being part of their classification criteria\(^\text{3,4}\).

Of note, IBD contributes to the diagnosis of axSpA, as it has a positive likelihood ratio of 4.3 for axSpA diagnosis in patients with chronic low back pain\(^\text{5}\).

According to the latest Assessment of SpondyloArthritis Society (ASAS) criteria, SpA can be classified to axSpA or peripheral SpA. The former pertains to patients with low back pain for ≥ 3 mo and imaging and age of onset < 45 years old and requires either sacroiliitis on imaging and at least one other SpA feature (e.g., dactylitis, enthesitis) or positivity for HLA-B27 and at least two other SpA features (Table 1)\(^\text{4}\). Difference between nraxSpA and axSpA is the lack of radiographically confirmed sacroiliitis in the former. Under the term “peripheral SpA” are classified patients without current low back pain, with peripheral arthritis, or enthesitis or dactylitis plus at least one or two of the following SpA features: (uveitis, psoriasis, crohn’s disease/ulcerative colitis, preceding infection, positive HLA-B27, sacroiliitis on imaging) or (arthritis, enthesitis, dactylitis, inflammatory back pain in the past, family history of SpA), respectively\(^\text{4}\).

It is well known that there is a close association between IBD and SpA\(^\text{7}\). Purpose of our review was to present in detail the existing epidemiological data and treatment approaches to these patients and to delineate the current diagnostic challenges. Also, we aimed to describe the underlying pathogenetic mechanisms that have been
DISEASE CHARACTERISTICS

IBD AND SPA: EPIDEMIOLOGY, AND ASSOCIATION WITH DISEASE CHARACTERISTICS

IBD in the context of SPA

IBD (including Crohn’s disease (CD) and ulcerative colitis (UC)) is not rare in AS, with its prevalence ranging from 6%-14%[1,2,3]. In detail, in a large population, control-matched study, including 4101 patients with AS, Stolwijk et al[3] found that at the time of AS diagnosis, the cumulative incidence was 4%. Additionally, in a French large, prospective study for early inflammatory back pain, IBD occurred in 7.2% of patients with newly diagnosed AS[4]. Furthermore, in an early axSpA cohort frequency of IBD was calculated to be 2.6% (1.7% for AS and 0.9% for nraxSpA, difference was not significant)[4]. In fact, it has been suggested that the risk for IBD is more pronounced in the first years of AS diagnosis and falls at baseline levels approximately 10 years after[5]. However, this has not been confirmed by a SLR and meta-analysis[6]. In that, Stolwijk et al[3] found that prevalence of IBD in AS was 6.8% (95%CI: 6.1%-7.7%), which is much higher than the percentages observed in the general population (0.01% to 0.5%). Likewise, in a large population study was shown that the incidence rate of IBD was 5.3-fold increased to the AS patients compared to healthy controls. For nraxSpA the results seem to be largely similar. In a meta-analysis addressing the
prevalence of extra-articular disease in nraxSpA versus AS, it was found that IBD was almost equally frequent (pooled prevalence difference of 1.4% in favour of AS) between these two entities. The question remains open whether we can predict which SpA patients suffer from or will develop IBD. Stolwijk et al. 2014 found that IBD was in general more common in males and that its frequency decreases with age, in AS. In a multi-centre AS study with a long follow-up, no differences were recorded between patients who had a history of IBD at baseline and those who did not. On the other hand, development of IBD was associated with disease activity and spinal pain scores at baseline and worse physical function and patient well-being, at the time of IBD diagnosis[37]. Additionally, in a case control study[23-25] it was found that anterior uveitis was less frequent in patients with IBD-related spondyloarthropathy compared to those with SpA without bowel involvement[26]. Interestingly, in a sub-analysis of the GIANT cohort, it was shown that in patients with axSpA, there is a link between bone marrow edema of the sacroiliac joints and the gut inflammation. For this, SPARCC (Spondyloarthritis Research Consortium of Canada) scores which is a tool to measure MRI-defined sacroiliitis and ileocolonoscopy were used, respectively. It was found that SPARCC scores were higher in patients with chronic gut inflammation, compared to those without gut lesions[27].

**Clinically silent IBD in SpA**

Despite clinically evident IBD in the context of AS is observed in less than 15%, it has been suggested that clinically silent macroscopic and microscopic gut inflammation occurs in about 60% of AS patients[14-20]. From then, 5%-20% will develop CD within 5 years[17,30]. Microscopic gut inflammation, in axSpA, has been associated with younger age, male gender, progressive disease, early disease onset, radiologic sacroiliitis, high disease activity as assessed by the BASDAI and restricted spinal mobility measured by the Bath Ankylosing Spondylitis Metrology Index[9,16]. No association was identified with other extra-articular features or with the status of HLA-B27. Results were comparable between nraxSpA and AS[14].

**SpA occurring in patients with IBD**

Seeing the opposite flip of the coin, SpA is encountered in about 10-39% of patients with IBD, being the most frequent extra-intestinal manifestation in these individuals[16,19-29]. SpA is more commonly observed in patients with CD compared to those with UC[29-30]. Axial/arthritis symptomatology usually follows IBD diagnosis, but in about 20% the opposite is the case[19,29] especially for axial disease[30]. In general, AS and sacroiliitis (symptomatic or not) is estimated to occur in about 2%-16% and 12%-46% of IBD patients, respectively[14-17,20,21], both being more common in CD than in UC[19,21]. In a recent meta-analysis, it was shown that prevalence of AS and sacroiliitis in IBD were 3% (95%CI: 2%-4%) and 10% (95%CI: 8%-12%), respectively.

Comparing CD patients with and without AS, in a small single centre study, Liu et al did not observe any differences between these two groups[31]. Of note, they demonstrated that there was a significant correlation between disease activities of these two entities. These were measured by CD activity index for CD and with BASDAI for AS. They also showed that activity of CD significantly correlated with functional disability in AS, as assessed by Bath AS functional index - BASFI. All these possibly imply that there is a tight connection in the pathogenetic mechanisms of these conditions.

On the other hand, in a study examining possible associations between clinical and other characteristics with the occurrence of AS or SI in patients with CD, it was found that there was an association between SI and peripheral arthritis as well as between AS and uveitis, in these patients[31]. Besides, it has been suggested that in CD patients, colitis is more commonly associated with arthritic involvement compared to patients suffering from ileitis, while regarding UC, it seems that isolated proctitis is rarely combined with rheumatic manifestations[32-34].

Finally, patients with IBD-related ankylosing spondylitis and IBD-related isolated sacroiliitis are HLA-B27 positive in about 25%-78% and 7%-15%, respectively[19,22,23,29], possibly suggesting that isolated sacroiliitis is of different nature compared to AS in the setting of IBD[25]. These percentages are also lower compared to the prevalence of HLA-B27 observed in patients with AS which range from 80%-90%[1-9,20,24-36].

Peripheral SpA is also common in CD with its prevalence ranging from 0.4% to 34.6%[18,23,35]. A recent systematic review and meta-analysis found that the pooled prevalence of peripheral arthritis, in the context of IBD was 13% (95%CI: 12%-15%) with its prevalence being much higher in the younger ages: 25% (95%CI: 19%-32%) and 2% (95%CI: 1%-5%) for age groups between 20-30 and 50-60 years old, respectively[31]. As observed for axial disease, peripheral SpA is more common in CD compared to UC[20,34-38]. A large retrospective study in the IBD Oxford clinics, had
shown that peripheral arthritis occurred in 10% and 6% of patients with CD and UC, respectively[20,21]. This study, led to identification of two major groups of peripheral arthritis in the context of IBD, namely: oligoarticular (< 5 joints are affected) and polyarticular (≥ 5 joints are affected)[20]. Some authors suggest that in the first group, which is more frequent than the second[20], arthritis is usually asymmetrical, non-erosive, affects lower limbs[18] and is associated with IBD activity and positivity for HLA-B27[20,21]. Patients belonging in the second group tend to have a more chronic course and be destructive and unrelated with IBD activity and HLA-B27 status[20]. Furthermore, Yüksel et al[20], examining the characteristics of peripheral arthritis in patients with IBD, they found that erythema nodosum and pyoderma gangrenosum were more commonly observed in IBD patients who also had peripheral arthritis, compared to those without. Various risk factors have been reported for peripheral arthritis in the context of IBD including: family history of IBD, appendectomy, smoking and presence of other extra-intestinal manifestations[21,22].

Finally, some IBD patients might exhibit clinical features of SpA (e.g., dactylitis) without fulfilling diagnostic criteria for SpA[23,24]. The frequency of dactylitis in patients with SpA in the context of IBD varies from 0% to 15.5%, but it seems to be around 5%[12,13] and therefore less common than in patients with SpA without IBD[14]. Incidence of enthesitis also varies largely, among different studies, in these patients[12,13]. A case control study[13] found that enthesitis was also less frequent in IBD-SpA patients compared to SpA individuals without IBD. For both dactylitis and enthesitis, no differences in their frequency were detected between CD and UC patients, while they occurred more frequently in patients with IBD and psoriasis compared to the IBD patients without skin disease[12].

**PATHOPHYSIOLOGY**

The pathophysiology of spondyloarthropathies associated with IBD involves the so-called “gut-synovial axis” hypothesis, which implicates environmental and host factors. Many of them act as triggers leading to initiation of inflammation in genetically predisposed individuals (Figure 1). Several studies have confirmed the link between joint and gut inflammation. It seems likely that both bacterial antigens and reactive T-cell clones, activated into the gut home the joint. However, the exact immunological mechanisms linking gut and joint inflammation are not fully understood[43,44].

**Genetic predisposition**

Genetic predisposition seems to carry a significant role in linking these conditions. In a large genotyping study, investigating risk variants for AS, it was shown that many of these were also linked with CD and UC[45]. Additionally, in a genealogic study in Iceland it was shown that first and second-degree relatives of patients with AS had increased risk (3.0 and 2.1, respectively) for IBD and vice versa[46].

Genetic factors play an important role, through alterations in both the adaptive and innate immune pathways[43,44]. Certain human leukocyte antigen (HLA) alleles have been recognized in patients with IBD who are at higher risk for having SpA. As mentioned, 25%-78% of patients with AS and IBD are positive for HLA class I molecule B27 (HLA-B27) [25,41,44]. Furthermore, MHC class II allele DRB1 0103 along with HLA-B35 and HLA-B27 are frequently associated with type I peripheral arthritis[43,47,48], while approximately 38% of patients with active UC or CD have been identified as carrying the allele DRB1 0103. On the other hand, type II peripheral arthritis is associated with HLA-B44[41,49].

Genetic factors outside the HLA system, have also been described. Variations of CARD15 gene (which encodes the protein product NOD2) increase the risk of CD about 4-40 times and has been linked to the development of sacroiliitis in IBD patients[50,51]. In addition, patients with AS and CARD15 mutations are at higher risk for subclinical intestinal inflammation[42,43,45]. NOD2 is an intracellular receptor for bacterial molecules and is expressed in the surface of macrophages, lymphocytes, paneth cells and intestinal epithelial cells. This receptor plays a role in the innate immune response by activating nuclear factor-κB (NFκB) which is a transcriptional regulator of a large variety of genes encoding pro-inflammatory cytokines, adhesion molecules, cytokines, growth factors and enzymes[43,44,46,31,54]. As a result, NOD2 protein is responsible for positive regulation of immune defense in the gut and induction of a pro-inflammatory state[45]. However, though NOD2 gene mutations are associated with the clinical expression of CD in 20%-30% of patients there is no established association between presence of NOD2 mutations and development of SpA in IBD patients[43,52].
Figure 1  Pathogenic mechanisms linking gut and joint inflammation. The pathogenic link between spondyloarthropathies (SpAs) and inflammatory bowel disease (IBD) involves the so-called "gut-synovial axis" hypothesis. Various environmental (gut bacteria-dysbiosis) and host factors (migration of activated gut-T cells and macrophages) leading to initiation of inflammation in genetically predisposed individuals may act as triggers of inflammatory responses against gut and joints components. IBD patients carrying specific human leukocyte antigens (HLA) alleles (such as DRB1 0103 allele, HLA-B27, HLA-B35, HLA-B44) and mutations of the CARD15/NOD2 gene are at higher risk of developing SpAs. Recently, up-regulation of adhesion molecules (E-cadherin, αEβ7 integrin), increased levels of pro-inflammatory cytokines (tumor necrosis factor-α), macrophages expressing CD163 protein, interleukin (IL)-12/IL-23 signaling pathway and signal transducer and activator of transcription 3 protein have also been implicated in the pathophysiology of SpAs in IBD patients. IL: Interleukin; STAT: Signal transducer and activator of transcription; TNF: Tumor necrosis factor; HLA: Human leukocyte antigen; CARD15: Caspase recruitment domain-containing protein 15; NOD: Nucleotide-binding oligomerization domain-containing protein 2. Furthermore, CD, AS and PsA have been associated with polymorphisms in some common genes like IL-23R, IL-12B, STAT3, and CARD9, all of them implicated in the anti-IL-23/IL-17 axis\[^{56-60}\].

Having said that, IL-23/-17 axis seems to play an important role in both axSpA and IBD (regarding the latter, the evidence mainly pertains to CD rather than UC)\[^{61-63}\]. This axis is mainly regulated by IL-23, resulting in the production of IL-17, IL-22 and to a lesser extent of tumor necrosis factor (TNF)\[^{1}\] by the so-called Th17 cells, which are a subgroup of T-helper cells. These cytokines are also produced from other cells like innate lymphoid cells\[^{64}\]. In the gut of patients with CD or patients with SpA, it has been observed increased expression of IL-23\[^{65}\]. Similarly, in the peripheral blood of AS patients there is increased number of Tγδ cells expressing IL-23R and producing IL-17; additionally, increased expression of IL-23 is noticed in patients’ facets. Interestingly, it seems that there are some cells able to produce IL-17 irrespective of the presence of IL-23. This, as discussed below, might has some implications in the therapeutic approach of these patients\[^{66}\].

Links between the gut and the joints
Several other findings also highlight the common underlying pathogenetic mechanisms between IBD and SpA. αEβ7 integrin which is expressed by intraepithelial T cells in the intestinal mucosa and binds to the glycoprotein E-cadherin expressed by gut epithelial cells, has been found to be upregulated on colonic T cells from AS patients and also from lymphocytes obtained from synovial tissue of SpA patients\[^{67,68}\]. The E-cadherin molecules have been also observed to be up-regulated in the gut of patients with IBD and SpA individuals with subclinical gut inflammation\[^{67,68}\].

In another study increased levels of macrophages expressing the protein CD163 have been reported in both gut mucosa of IBD patients with and without SpA and in the synovial tissue and gut from SpA patients\[^{1,29}\]. Finally, animal models have shown that prolonged exposure to the pro-inflammatory cytokine TNF-α might lead to a phenotype resembling IBD-SpA\[^{27}\]. In the last decade, it was recognized that a common target of this cytokine could be the synovial fibroblasts and the intestinal myofibroblasts\[^{28,29}\].

The Gut-synovial axis
Two - probably complementary- theories have been formulated to explain the development of SpA in patients with IBD. These theories include both alterations in gut bacteria and migration of gut lymphocytes to the joint\[^{43,44}\]. Changes in the gut
microbiome, which is also known as dysbiosis, have been associated with SpA. In detail, *Faecalibacterium prausnitzii* has been found to be in reduced numbers, in stools of SpA patients\(^\text{[18,74]}\). Also, in AS patients, increased numbers of *Dialister* microbes in ileal and colon biopsies have been correlated with Ankylosing Spondylitis Disease Activity Score (ASDAS)\(^\text{[18,75]}\) and of *Ruminococcus gnavus* in the stools with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)\(^\text{[18,76,77]}\). Furthermore, other studies have detected in the inflamed joints of these patients certain bacteria like *Yersinia enterocolitica*, *Salmonella enteritidis* and *typhimurium*, or antigens related to them\(^\text{[20,75,79]}\). Role of microbiome in the pathogenesis of SpA is also supported by data from animal models. For example, the arthritis and inflammatory colitis features developed in HLA-B27 transgenic rats are ameliorated when they are raised in germ-free conditions\(^\text{[18,78]}\). These observations suggest that gut and joint inflammation process depends on the presence of bacteria into the gastrointestinal tract, which emphasizes the role of autoimmunity and antigen mimicry\(^\text{[18,79]}\).

The second hypothesis is based on experimental studies which showed that gut T-cells activated by antigens migrate to the joints and induce inflammation\(^\text{[18,43]}\). In state of inflammation alterations occur in the mucosal vasculature, such as vasodilatation, hyperemia and increased vascular permeability which are induced by various inflammatory cytokines, resulting in enhanced extravasation of leukocytes. Furthermore, the migration pathways of lymphocytes are altered by aberrant expression patterns of adhesion molecules, inflammatory cytokines and receptors\(^\text{[90]}\). It is known that integrins α4β7 and αΕβ7 and MadCAM-1 mucosal vascular receptor play an important role in the lymphocytes' gut homing. It has been shown that leukocytes populations from inflamed gut can bind to synovial vessels and home into the joint, using multiple adhesion molecules\(^\text{[91]}\), such as αΕβ7 integrins, vascular adhesion protein-1 (VAP-1) and intracellular adhesion molecule-1 (ICAM-1/CD54)\(^\text{[92]}\). The increased number of T cells expressing αΕβ7 integrins in the synovial membrane is in favor of the mucosal origin of these cells, however this hypothesis remains to be proven\(^\text{[90]}\).

Additionally, It has been shown that macrophages from the gut of IBD patients are able to adhere in endothelial cells of synovial tissue\(^\text{[93]}\), further enhancing the activation of T cells locally\(^\text{[94]}\). Collectively, one could argue that gut T-cells are activated in the Peyer’s patches and mesenteric lymph nodes, express a pattern of adhesion molecules that under specific conditions leads to migration of these activated T-cells into the joint causing inflammation\(^\text{[90,43]}\). Further studies are needed to fully understand the pathogenic pathways linking IBD and SpA.

### TREATMENT

Given the common pathogenetic mechanisms underlying SpA and IBD, therapeutic approach to these entities is largely similar. However, there are some differences in the safety and efficacy of the various treatment modalities used.

Non-steroidal anti-inflammatory drugs (NSAIDs) although commonly used in SpA, should be generally avoided in IBD especially in the active ones, but short courses (e.g., 2 wk) do not seem to cause exacerbations\(^\text{[95]}\). On the other hand, short courses of systemic steroids, although demonstrate some efficacy for CD or UC are not effective for axSpA\(^\text{[96]}\). Local steroids injections and low doses of systemic steroids have been used for peripheral SpA\(^\text{[97]}\).

The most common conventional Disease modifying antirheumatic drugs (DMARDs) used for treatment of SpA are methotrexate and sulfasalazine, both demonstrating some efficacy for peripheral but not for axial SpA\(^\text{[98,99]}\). Furthermore, methotrexate has proved to be helpful in inducing and maintaining remission in CD patients\(^\text{[100,97]}\) but is not recommended as first line treatment of UC. Similarly, sulfasalazine has some efficacy in CD (but not for ileal CD)\(^\text{[98]}\) and UC\(^\text{[99,100]}\).

Anti-TNF regimes are the gold-standard treatment for the patients with co-existing IBD with SpA who are not controlled with conventional DMARDs. All of them are approved for the treatment of axSpA\(^\text{[101]}\) while infliximab and adalimumab are the most well studied for patients with IBD, both having indication for CD and UC\(^\text{[102]}\). Etanercept, was not effective for IBD\(^\text{[103]}\). Many hypotheses have been made to explain its lack of efficacy, including that this might be related to its insufficiency to induce apoptosis in the T cells of the lamina propria\(^\text{[104]}\). Also, etanercept blocks both TNFa and TNFb. The latter seems to regulate, in the lamina propria, T-cell dependent IgA production, which in turn controls the intestinal microbiota composition\(^\text{[105]}\).

Interestingly, new onset IBD in the context of AS, has been observed in patients who started treatment with anti-TNF reagents\(^\text{[106,99]}\). These cases were more frequently resembling CD rather than UC and have been associated with commencement of
etanercept\textsuperscript{[97-99]}: Of note, a large multicentre AS study examining the presence and development of extra-articular manifestations did not find any correlation between biologics use and development of IBD\textsuperscript{[98]}. Whether there is a true association between treatment with anti-TNF drugs in AS patients and new-onset of IBD, remains to be defined.

The role of the IL-23/-IL-17 axis in the pathogenesis of SpA and IBD is supported by many studies of basic and clinical research\textsuperscript{[105]}. Despite, monoclonal antibodies targeting the key cytokines of the axis (i.e., IL-23 and IL-17) were thought to be very effective, data from clinical trials did not fully support this notion. Ustekinumab, a monoclonal antibody against the common p40 subunit of IL-12 and IL-23, has proved to be effective for CD but does not appear to work for AS. Although data derived from post hoc analyses of phase 3 trials in patients with psoriatic spondylitis were promising, ustekinumab did not achieve the primary endpoint in phase 3 trials for AS and non-radiographic axSpA\textsuperscript{[102]}. Similarly, risankizumab, which is an antibody specifically targeting the p19 subunit of IL-23 failed to show clinical and radiological efficacy in a phase 2 trial for AS\textsuperscript{[103]}. Data from clinical trial about other antibodies against p19 subunit of IL-23 are eagerly awaited. To explain the differences observed in the efficacy of anti-IL-23 between psoriatic spondylitis and AS, it is not irrational to speculate that the pathogenetic mechanisms underlying AS are somewhat different to those of spondylitis in the context of PsA.

Secukinumab, which is a monoclonal antibody against IL-17 recently received approval for AS and therefore is another therapeutic option in patients with axSpA. Phase 3 trials are now underway for secukinumab in nraxSpA. One could expect, based on the underlying pathogenetic mechanisms that secukinumab would have good results in CD. However, results in phase 2 trials were negative with the drug being numerically worse than placebo. Many hypotheses have been formed to explain the failure of secukinumab in CD. Candida albicans proliferation has been proposed as a plausible explanation for the CD exacerbation given the role of IL-17 in fighting fungal infections\textsuperscript{[101,102]}. Although new cases of IBD in axSpA patients treated with secukinumab have been described\textsuperscript{[106]}, a recently published study analysing data from 21 clinical trials from patients with psoriasis, psoriatic arthritis and ankylosing spondylitis, has shown that exposure adjusted incidence rates for IBD did not increase over time with secukinumab treatment\textsuperscript{[107,108]}. Interestingly, a recent study provided some evidence supporting that suppression of IL-17F but not IL-17A was indeed protective for colitis by inducing T regulatory cells via modifications in colonic microbiota\textsuperscript{[109]}. An obvious question is how ustekinumab, which blocks IL-23 and subsequently IL-17 works for CD but secukinumab does not? There is accumulated evidence that IL-17 can be produced also -to a lesser extent possibly- in an IL-23 independent manner from innate lymphoid, T γδ or other types of cells\textsuperscript{[104,106]}. Therefore, blocking IL-23 leaves some “basal” levels of IL-17. Lee et al\textsuperscript{[107]} have shown, that T γδ cells in the lamina propria are the producers of gut-protective IL-17, in an IL-23 independent way. Its effect is possibly mediated through regulation of the tight-junction protein “occludin” which maintain barriers integrity.

Vedolizumab, a gut selective α4β7 integrin antagonist, has shown to be effective in patients with CD\textsuperscript{[108,109]} and for inducing or maintaining therapy in UC patients\textsuperscript{[110]}. Results of this drug in articular symptoms are somewhat conflicting. Whether this drug is linked with exacerbation or new-onset arthralgias or inflammatory arthritis remains to be answered\textsuperscript{[107,111-113]}. Of note, a recent post hoc analysis of the “Gemini” trials showed that vedolizumab was associated with decreased likelihood of new or worsening arthritis/arthralgia in CD patients while in UC the incidence was similar between patients treated with the active drug or with placebo\textsuperscript{[114]}. JAK inhibitors are a new drug class category with promising results in various immune mediated diseases. Genome wide association studies have shown that there is association between CD and single nucleotide polymorphisms in the JAK-STAT pathway\textsuperscript{[115]}. Results in a phase 2 trial for CD has shown that tofacitinib was not effective\textsuperscript{[116]}. However, newer and more selective JAK-inhibitors, like filgotinib and upadacitinib have favorable results in achieving clinical remission in phase 2 trials for CD\textsuperscript{[117,118]}. For UC, tofacitinib after the promising results with patients achieving higher rates of clinical remission and clinical response compared to placebo\textsuperscript{[119]} received Food and Drug Administration (FDA) approval for patients with moderate to severe active UC.

As regards to the efficacy of JAK-inhibitors in SpA, tofacitinib has shown favorable results in phase 2 trials of AS with 80.8% of the patients treated with tofacitinib achieving ASAS20 improvement at week 8, compared to 41.2% of placebo-treated patients\textsuperscript{[120]}. Recently published results from a phase 2 clinical trials showed also that filgotinib was effective for AS with patients experiencing significant clinical improvement, compared to placebo, at week 12. A phase 2b/3a clinical trial assessing
the efficacy and safety of upadacitinib in patients with AS is currently underway (NCT03178487). Whether JAK-inhibitors could be another potential therapeutic option in patients with IBD and SpA remains to be defined from future studies.

**DIAGNOSIS - THE ROLE OF CALPROTECTIN**

Although colonoscopy is being considered as the gold-standard for IBD diagnosis, a recent study has shown that capsule endoscopy was superior to classical colonoscopy in diagnosing CD in the context of SpA. It was shown that small bowel inflammation was present in 42.2% and 10.9% of the patients who underwent capsule endoscopy and classical colonoscopy, respectively. Interestingly, positive findings were not associated with symptomatology from the gastrointestinal system but with elevated faecal calprotectin levels, confirming that many SpA patients have “silent” IBD.[12] Calprotectin measured in the serum or in the stools has been used to identify subclinical bowel inflammation in patients with SpA. Cypers et al.[14] have found that elevated serum calprotectin levels have been associated with subclinical microscopic colitis in SpA patients. In detail, individuals who had both CRP and calprotectin elevated had a frequency of bowel inflammation of 64% compared to 25% in patients who had low levels of these proteins. Additionally, in patients who had high levels of either serum calprotectin or CRP, frequency of bowel inflammation was significantly higher in SpA patients with high faecal calprotectin compared to those with low.[15] In a recent study, Østgard et al.[16] confirmed that faecal calprotectin could serve as a biomarker to identify patients with subclinical bowel inflammation. It has to be noted however that faecal calprotectin levels can be influenced by NSAIDs use, which is quite common in SpA patients.[12] Interestingly, patients with elevated faecal calprotectin levels had more inflammation in the sacroiliac joints compared to those with low levels. Also, the former had better response to adalimumab as assessed by ASDAS. It has to be said however, that these patients received an extra loading dose of 80 mg adalimumab, at baseline[12]. The concept of calprotectin as biomarker of treatment response has been suggested also previously: In proof of concept trials for SpA, serum calprotectin has been found to be decreased after treatment of axSpA and peripheral SpA with infliximab and etanercept, respectively.[14]

**DISCUSSION - POINTS TO CONSIDER**

It is increasingly being recognized that there is a very close link between IBD and SpA. As outlined in this review, there are several hints for that: epidemiological, clinical, laboratory (i.e., positivity for HLA-B27) histopathologic and pathogenetic. Regarding the latter, it is very intriguing to define to which extent these are common between these entities and identify the diversities that lead to different clinical expressions. However, many limitations impede this venture. Firstly, over the last years, many different criteria have been used for the classification of SpA, which comprise a group of relatively heterogenous diseases. Besides, classification criteria in SpA do not mean necessarily a certain diagnosis and vice versa[13]. Secondly, these patients, depending on the cardinal manifestation, are followed up by a gastroenterologist or a rheumatologist that might overlook the articular or bowel manifestations of the disease, respectively. To that end, the effective communication between different professions and the interdisciplinary approach, through combined clinics for example, is imperative.

Treatment of this entities has progressed significantly over the last years. To the successful anti-TNF reagents, drugs targeting IL-23 and IL-17 as well as the JAK-inhibitors have been added to the clinician’s arsenal. However, treating patients with co-existing SpA and IBD, should not only include these manifestations but also considerate other extra-articular and extra-intestinal manifestations like skin disease or uveitis. Comprehensive algorithms, designed by clinicians of many disciplines are urgently needed, in light of the numerous emerging therapeutic modalities.

**REFERENCES**

1. Klitz U, Siebert S, Frargoulis G, McInnes I. Spondyloarthritides: Pathogenesis, Clinical aspects and Diagnosis. In: Bijlsma JW, Hachulla E. EULAR Textbook on Rheumatic Diseases. BMJ Publishing group 2018; 338-364
2. Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. *Ann Rheum Dis* 2015; 74: 65-73 [PMID: 23999006 DOI: 10.1136/annrheumdis-2013-203582]
Incidence of spondyloarthropathy in patients with Crohn’s disease: a population-based study. *J Rheumatol*, Loftus EV, Tremaine WJ, Bongartz T, Harmsen WS, Zinsmeister AR, Matteson EL.

Shivashankar R, Calabrese C, Rizzello F. Inflammatory Bowel Diseases and Spondyloarthropathies. *J Gastroenterol Hepatol* 2014; 29: 1696-1703 [PMID: 8964393]

Gilis E, Mortier C, Venken K, Debschere K, Vereecke L, Elewaut D. The Role of the Microbiome in Gut and Joint Inflammation in Psoriatic Arthritis and Spondyloarthritis. *J Rheumatol Suppl* 2018; 94: 36-39 [PMID: 29858332 DOI: 10.3899/jrheum.180115]

Gionchetti P, Calabrese C, Rizzello F. Inflammatory Bowel Diseases and Spondyloarthropathies. *J Rheumatol Suppl* 2015; 93: 21-23 [DOI: 10.3899/jrheum.150628]

Gionchetti P, Castiglione F, Felice C, Gionchetti P, Orlando A, Salvarani C, Scarpai R, Vecchi M, Armuzzi A. Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. *Autoimmun Rev* 2013; 12: 822-830 [PMID: 24726868 DOI: 10.1016/j.autrev.2014.04.003]

Orlando A, Renna S, Perricone G, Cottone M. Gastrointestinal lesions associated with spondyloarthropathies. *World J Gastroenterol* 2009; 15: 2443-2448 [PMID: 19468992 DOI: 10.3748/wjg.15.2443]

de Winter JJ, Mens LJ, van der Heijde D, Landewé R, Baeten DL. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. *Arthritis Res Ther* 2016; 18: 196 [PMID: 27586785 DOI: 10.1186/s13075-016-1093-z]

Essers I, Ramiro S, Stolwijk CJ, Blauw M, Landewé R, van der Heijde D, Van den Bosch F, Dougdas M, van Tubergen A. Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. *Rheumatology (Oxford)* 2015; 54: 633-640 [PMID: 25234663 DOI: 10.1093/rheumatology/keu388]

Dougdas M, d’Agostino MA, Benessiano J, Berenbaum F, Breban M, Claudépie P, Combe B, Dargent-Molina P, Darrière JP, Fautrel B, Feydy A, Goupil P, Leblanc V, Logeat I, Pham T, Richette P, Roux C, Rudwaleit M, Saraux A, Treluyer JM, van der Heijde D, Wendling D. The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France. *Ann Rheum Dis* 2014; 73: 193-197 [PMID: 24658834 DOI: 10.1136/annrheumdis-2015-208025]

Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. *Best Pract Res Clin Rheumatol* 2006; 20: 451-473 [PMID: 17077579 DOI: 10.1016/j.berh.2006.03.010]

Van Praet L, Van den Bosch FE, Jacques P, Carron B, Loo K, Colman R, Peeters H, Mielants H, De Vos M, Cuvelier C, Van den Bosch F, Elewaut D. Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort. *Ann Rheum Dis* 2014; 73: 1186-1189 [PMID: 24726668 DOI: 10.1136/annrheumdis-2013-203854]

Cypers H, Varkas G, Beeckman S, Debschere K, Vogl T, Roth J, Drennan MJ, Lavric M, Foell D, Cuvelier CA, De Vos M, Delangle J, Van den Bosch F, Elewaut D. Elevated calprotectin levels reveal bowel inflammation in ankylosing spondylitis. *Ann Rheum Dis* 2016; 75: 1357-1362 [PMID: 26698844 DOI: 10.1136/annrheumdis-2015-208025]

Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. *Best Pract Res Clin Rheumatol* 2006; 20: 451-473 [PMID: 17077579 DOI: 10.1016/j.berh.2006.03.010]

Van Praet L, Van den Bosch FE, Jacques P, Carron B, Loo K, Colman R, Peeters H, Mielants H, De Vos M, Cuvelier C, Elewaut D. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. *Ann Rheum Dis* 2013; 72: 414-417 [DOI: 10.1136/annrheumdis-2012-202135]

De Vos M, Mielants H, Cuvelier C, Elewaut A, Veys E. Long-term evolution of gut inflammation in patients with spondyloarthritis. *Gastroenterology* 1996; 110: 1696-1703 [PMID: 8964393]

Gils E, Mortier C, Venken K, Debschere K, Vereecke L, Elewaut D. The Role of the Microbiome in Gut and Joint Inflammation in Psoriatic Arthritis and Spondyloarthritis. *J Rheumatol Suppl* 2018; 94: 36-39 [PMID: 29858332 DOI: 10.3899/jrheum.180115]

Gionchetti P, Calabrese C, Rizzello F. Inflammatory Bowel Diseases and Spondyloarthropathies. *J Rheumatol Suppl* 2015; 93: 21-23 [DOI: 10.3899/jrheum.150628]

Olivieri I, Cantini F, Castiglione F, Felice C, Gionchetti P, Orlando A, Salvarani C, Scarpai R, Vecchi M, Armuzzi A. Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. *Autoimmun Rev* 2013; 12: 822-830 [PMID: 24726868 DOI: 10.1016/j.autrev.2014.04.003]

Orchard TR, Holt H, Bradbury L, Hammersma J, McNally E, Jewell DP, Wordsworth BP. The prevalence, clinical features and association of HLA-B27 in sacroiliitis associated with established Crohn's disease. *Aliment Pharmacol Ther* 2009; 29: 193-197 [PMID: 18945256 DOI: 10.1111/j.1365-2636.2008.03684.x]

Palm O, Moun B, Onge A, Gran JT. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). *J Rheumatol* 2002; 29: 511-515 [PMID: 11905854]

Salvarani C, Fries W. Clinical features and epidemiology of spondyloarthopathies associated with inflammatory bowel disease. *World J Gastroenterol* 2009; 15: 2449-2455 [PMID: 19468993]

Shivashankar R, Loftus EV, Tremaine WJ, Bongartz T, Harnsen WS, Zimmeister AR, Matteson EL. Incidence of spondyloarthropathy in patients with Crohn's disease: a population-based study. *J Rheumatol* 2012; 39: 2148-2152 [DOI: 10.3899/jrheum.120021]

Smale S, Natt RS, Orchard TR, Russell AS, Bjarnason I. Inflammatory bowel disease and spondyloarthropathy. *Arthritis Rheum* 2001; 44: 2728-2736 [PMID: 11762932]
26 Fantini MC, Pallone F, Monteleone G. Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies. *World J Gastroenterol* 2009; 15: 2472-2478 [PMID: 19468997]

27 Turkcanapar N, Toruner M, Soykan I, Aydintug OT, Cetinkaya H, Durzun N, Ozen A, Duman M. The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease. *Rheumatol Int* 2006; 26: 663-668 [PMID: 16136311 DOI: 10.1007/s00296-005-0044-9]

28 Yüksel I, Ataseven H, Başar O, Köklü S, Ertuğrul I, Ulker A, Dağlı U, Şanşaz N. Peripheral arthritis in the course of inflammatory bowel diseases. *Dig Dis Sci* 2011; 56: 183-187 [PMID: 20453624 DOI: 10.1007/s10620-010-1260-z]

29 de Vlam K, Mielants H, Cuvelier C, De Keyser F, Veys EM, De Vos M. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. *J Rheumatol* 2000; 27: 2860-2865 [PMID: 11128677]

30 Karreman MC, Luime JJ, Hazes JMW, Weel AEAM. The Prevalence and Incidence of Axial and Peripheral Spondyloarthritides in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. *J Crohns Colitis* 2017; 11: 631-642 [PMID: 28455761 DOI: 10.1016/j.jcjo.2016.04.002]

31 Liu S, Ding J, Wang M, Zhou W, Feng M, Guan W. Clinical features of Crohn disease concomitant with ankylosing spondylitis: A preliminary single-center study. *Medicine (Baltimore)* 2016; 95: e2467 [PMID: 27428240 DOI: 10.1097/MD.0000000000002467]

32 Peeters H, Vander Cruyssen B, Mielants H, de Vlam K, Vermeire S, Louis E, Rutgeerts P, Belaiche J, De Vos M. Clinical and genetic factors associated with sacroilitis in Crohn’s disease. *J Gastroenterol Hepatol* 2008; 23: 132-137 [PMID: 17725592 DOI: 10.1111/j.1440-1746.2007.05108.x]

33 Steer S, Jones H, Hibbert J, Kondeatis E, Vaughan R, Sanderson J, Gibson T. Low back pain, sacroilitis, and the relationship with HLA-B27 in Crohn’s disease. *J Rheumatol* 2003; 30: 518-522 [PMID: 12610811]

34 Alamannos Y, Papapoulopoulos NG, Voulgari PV, Karakatsanis A, Sirou C, Drosos AA. Epidemiology of ankylosing spondylitis in Northwest Greece, 1983-2002. *Rheumatology (Oxford)* 2004; 43: 615-618 [PMID: 14872102 DOI: 10.1093/rheumatology/keh133]

35 Farat SN, Yazici A, Yilmazer B, Coşan F, Salihi V, Celie A. Low frequency of HLA-B27 in ankylosing spondylitis and its relationship with clinical findings in patients from Turkey. *Eur J Rheumatol* 2017; 4: 268-271 [PMID: 29308262 DOI: 10.1155/2017/1710591]

36 Khan MA. Spondyloarthropathies. *Curr Opin Rheumatol* 1994; 6: 351-353 [PMID: 8068505]

37 Peluso R, Di Minno MN, Iervolino S, Manguo F, Tramontano G, Ambrosino P, Esposito C, Scalera A, Castiglione F, Scarpia R. Enteropathic spondyloarthropathies: from diagnosis to treatment. *Clin Dev Immunol* 2013; 2013: 631408 [PMID: 23690825 DOI: 10.1155/2013/631408]

38 Rodriguez-Reyna TS, Martinez-Reyes C, Yamamoto-Furusho JK. Rheumatic manifestations of inflammatory bowel disease. *World J Gastroenterol* 2009; 15: 5517-5524 [PMID: 19938189 DOI: 10.3748/wjg.15.5517]

39 Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. *Gut* 1998; 42: 387-391 [PMID: 9577430]

40 Manguo F, Sanges M, Suiano T, Gargiulo S, Nastas P, Gargano D, Somma P, Mansueto G, Peluso R, Scarpia R, D’Arienzo FP, Astariotia C, Ayala F, Renda A, Mazzaeca G, D’Arienzo A. Cigarette smoking and appendectomy are risk factors for extraintestinal manifestations in ulcerative colitis. *Am J Gastroenterol* 2004; 99: 327-334 [PMID: 15046225]

41 Vasnicka SR, Brun I, Ballabeni P, Wittet P, Prinz Vavricka BM, Zeitz J, Rogler G, Schoepfer AM. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. *Am J Gastroenterol* 2011; 106: 110-119 [PMID: 20808297 DOI: 10.1038/ajg.2010.343]

42 Queiro R, Maiz O, Intxausti J, de Dios JR, Belunegui J, Gonzalez C, Figueroa M. Subclinical sacroilitis in inflammatory bowel disease: a clinical and follow-up study. *Clin Rheumatol* 2000; 19: 445-449 [PMID: 11147753]

43 Arvikar SL, Fisher MC. Inflammatory bowel disease associated arthropathy. *Curr Rev Musculoskelet Med* 2011; 4: 123-131 [PMID: 21710141 DOI: 10.1016/j.cms.2011.09.005]

44 Sheh T, Pitchumoni CS, Das KM. Management of Musculoskeletal Manifestations in Inflammatory Bowel Disease. *Gastroenterol Hepatol Rev* 2015; 2015: 387891 [PMID: 26170832 DOI: 10.1155/2015/387891]

45 International Genetics of Ankylosing Spondylitis Consortium, Australo-Anglo-American Spondyloarthritides Consortium (TASC), Groupe Francais d’Etude Genetique des Spondylarthrites (GFEGS), Nord-Trondelag Health Study (HUNT), Spondyloarthropathies Research Consortium of Canada (SPARCC), Wellcome Trust Case Control Consortium 2 (WTCCC2). Cortes A, Hadler J, Pointon JP, Robinson PC, Karadere T, Loo P, Cremin K, Pryce K, Harris J, Lee S, Ioo KB, Shim SC, Weisman M, Ward M, Zhou X, Garchon HJ, Chiocchia G, Donnelly J, Yoo B, Breslow N, Gafney K, Gaston H, Gladman DD, Rahman P, Maksymowycz WP, Xu H, Cruissius JB, Chou CT, Hansen IM, Ridon V, Martin J, Breban M, Revillle JD, Evans DM, Kim TH, Wordsworth DP, Brown MA, Bargoin-Vargas R, Fernandez-Suerdo JL, Gonzalez-Gay MA, Lopez-Larrea C, Romero-Sanchez C, Pimentel-Santos FM, Valle-Oñate R, van der Horst-Bruinsma IE, Frere O. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. *Nat Genet* 2013; 45: 730-738 [PMID: 23749187 DOI: 10.1038/ng.2667]

46 Thjodhleifsson B, Geirsson AJ, Bjornsson S, Bjarnason I. A common genetic background for inflammatory bowel disease and ankylosing spondylitis: a genetic study in Iceland. *Arthritis Rheum* 2007; 56: 2633-2639 [PMID: 17665420 DOI: 10.1002/art.22812]

47 Orchard TR, Thyagaraja S, Welsh Ki, Wordsworth BP, Hill Gaston JS, Jewell DP. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. *Gastroenterology* 2000; 118: 274-278 [PMID: 10648455]

48 Voulgari PV. Rheumatological manifestations in inflammatory bowel disease. *Ann Gastroenterol* 2011; 24: 173-180 [PMID: 24717171]

49 Jewell D. Do HLA-antigens predict the occurrence of extraintestinal manifestations of IBD? *Inflamm Bowel Dis* 2008; 14 Suppl 2: S28 [PMID: 18816758 DOI: 10.1007/s10034-007-0272-x]

50 Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. *Nat Rev Immunol* 2003; 3: 521-533 [PMID: 12876555 DOI: 10.1038/nri132]

51 Brakenhoff LK, van der Heijde DM, Hommes DW, Huizinga TW, Fidder HH. The joint-gut axis in inflammatory bowel diseases. *J Crohns Colitis* 2010; 4: 257-268 [PMID: 21122514 DOI: 10.1016/j.crohns.2009.11.005]
52 Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliukas R, Duerr RH, Ackiar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-606 [PMID: 11385577 DOI: 10.1038/sj.35079114]

53 Lautens D, Peeters H, Marichal D, Vander Cruyssen B, Mieltans H, Elewaft D, Demetter P, Cuvelier C, Van Den Bergh M, Rottiers P, Veys EM, Remaut E, Steidler L, De Keyser F, De Vos M. CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease. Ann Rheum Dis 2005; 64: 930-935 [PMID: 15594433 DOI: 10.1136/ard.2004.028337]

54 Abraham C, Cho JH. Functional consequences of NOD2 (CARD15) mutations. Inflamm Bowel Dis 2006; 12: 641-650 [PMID: 16804402 DOI: 10.1097/01.MIB.0000225332.8368.51]

55 Hampe J, Cuthbert B, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, Frenzel H, King K, Hasselmeyer A, MacPherson AJ, Bridger S, van Deventer S, Forbes A, Nikolaus S, Lemond-Jones JE, Foelsch UR, Krawczak M, Lewis C, Schreiber S, Mathew CG. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001; 357: 1925-1928 [PMID: 11425413 DOI: 10.1016/S0140-6736(00)05603-7]

56 Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 2011; 140: 1704-1712 [PMID: 21530736 DOI: 10.1053.j.gastro.2011.02.046]

57 Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinbart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Braton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barramda MM, Rotter JJ, Nicolae DL, Cho JH. A genome-wide association study identifies IL-23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-1463 [PMID: 17988223 DOI: 10.1126/science.1135245]

58 Rahman P, Inman RD, Gedman DD, Reeve JP, Peddle L, Maksymyckow WP. Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum 2008; 58: 1020-1025 [PMID: 18383363 DOI: 10.1002/art.23389]

59 Danoy P, Pycke K, Hadjler J, Bradbury LA, Farrar C, Pointon J; Australo-Anglo-American Spondyloarthropathies Consortium, Ward M, Weisman M, Reveille JD, Wordsworth BP, Stone MA; Spondyloarthritis Research Consortium of Canada, Maksymyckow W, Gedman DD, Inman RD, Brown MA. Association of variants at Iq32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease. PLoS Genet 2010; 6: e1001195 [PMID: 21152001 DOI: 10.1371/journal.pgen.1001195]

60 Nanda S. Spondyloarthropathies: novel genetic variants link ankylosing spondylitis and Crohn disease: evidence of a shared pathogenesis? Nat Rev Rheumatol 2011; 7: 70 [PMID: 21374899]

61 Fragoulis GE, Siebert S, McInnes IB. Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases. Annu Rev Med 2016; 67: 337-353 [PMID: 26565676 DOI: 10.1146/annurev-med-051914-021944]

62 Fries W. Inflammatory bowel disease-associated spondyloarthropathies. World J Gastroenterol 2009; 15: 2441-2442 [PMID: 19468991 DOI: 10.3748/wjg.v15.i24.2441]

63 Liossis NS, Daoussis D. Is there a link between IL-23/IL-17 and developmental pathways such as the Wnt and Hedgehog pathway? Mediators J Rheumatol 2017; 28: 69-71

64 Hasegawa E, Sonoda KH, Shichita T, Morita R, Sekiya T, Kimura Y, Takeda A, Yoshimura T, Yoshida S, Ishibashi T, Yoshimura A. IL-23-independent induction of IL-17 from γδT cells and innate lymphoid cells promotes experimental intraocular neovascularization. J Immunol 2013; 190: 1778-1787 [PMID: 23319736 DOI: 10.4049/jimmunol.1202495]

65 Ciccia F, Bombardieri M, Principato A, Giardina A, Tripodo C, Porcasi R, Peralta S, Franco V, Giardina E, Craxi A, Pithals C, Triolo G. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum 2009; 60: 955-965 [PMID: 19333939 DOI: 10.1002/art.24389]

66 Siebert S, Millar NL, McInnes IB. Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? Ann Rheum Dis 2018; 77: 689-702 [PMID: 25488778 DOI: 10.1002/berh.10018]

67 Jacques P, Elewaft D. Joint expedition: linking gut inflammation to arthritis. mucosal inflammation. 2008; 1: 364-371 [PMID: 1907920 DOI: 10.1038/mi.2008.24]

68 Demetter P, Baeten D, De Keyser F, De Vos M, Van Damme N, Verbruggen G, Vermeulen S, Mareel M, Elewaft D, Mieltans H, Veys EM, Cuvelier CA. Subclinical gut inflammation in spondyloarthropathy patients is associated with upregulation of the E-cadherin/catenin complex. Ann Rheum Dis 2000; 59: 211-216 [PMID: 10700430]

69 Baeten D, Demetter P, Cuvelier CA, Kruhthof E, Van Damme N, De Vos M, Veys EM, De Keyser F. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol 2002; 196: 343-350 [PMID: 11857499 DOI: 10.1002/path.1044]

70 Demetter P, De Vos M, Van Huyse JA, Baeten D, Feradnande L, Peeters H, Mielants H, Veys EM, De Keyser F, Cuvelier CA. Colon mucosa of patients both with spondyloarthropathy and Crohn's disease is enriched with macrophages expressing the scavenger receptor CD163. Arthritis Rheum 2005; 64: 321-324 [PMID: 15166002 DOI: 10.1002/ard.20383]

71 Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999; 10: 387-398 [PMID: 10204634]

72 Armakl M, Apostolaki M, Jacques P, Kontoyiannis DL, Elewaft D, Kollias G. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med 2008; 205: 331-337 [PMID: 18250193 DOI: 10.1084/jem.20070906]

73 Stolf ML, Kumar R, Morrow CD, LeFkowitz EJ, Cui X, Genn A, Cron RQ, Elson CO. Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis-related arthritis. Arthritis Res Ther 2014; 16: 486 [PMID: 25344931 DOI: 10.1186/1745-3674-16-486]

74 Tito RY, Cypers H, Joossens M, Varkas G, Van Praet L, Glorieus E, Van den Bosch F, De Vos M, Raes J, Elewaft D. Brief Report: Dialister as a Microbial Marker of Disease Activity in Spondyloarthropathy. Arthritis Rheumatol 2017; 69: 114-121 [PMID: 2739007 DOI: 10.1002/art.39802]

75 Breban M, Tap J, Leboine A, Said-Nahal R, Langella P, Chiochetta G, Furet JP, Sokol H. Fecal microbiota study reveals specific dysbiosis in spondyloarthropathy. Ann Rheum Dis 2017; 76: 1614-1622
Fragoulis GE et al. IBD and SpA

[PMID: 28606969 DOI: 10.1136/annrheumdis-2016-211064]

77 Vereecke L, Elewaat D. Spondyloarthropathies: Ruminococcus on the horizon in ankyrotic disease. *Nat Rev Rheumatol* 2017; 13: 574-576 [PMID: 28014815 DOI: 10.1038/nrrheum.2017.130]

78 Granfors K, Jalkanen S, Lindberg AA, Mäki-Ikola O, von Essen R, Lahesmaa-Rantala R, Isomäki H, Saario R, Arnold WJ, Toivanen A. Salmonella lipopolysaccharide in synovial cells from patients with reactive arthritis. *Lancet* 1990; 335: 685-688 [PMID: 1690327]

79 Granfors K, Jalkanen S, von Essen R, Lahesmaa-Rantala R, Isomäki O, Pekkola-Heino K, Merilahiti-Palo R, Saario R, Isomäki H, Toivanen A. Versinia antigens in synovial-fluid cells from patients with reactive arthritis. *N Engl J Med* 1989; 320: 216-221 [PMID: 3524047 DOI: 10.1056/NEJM198901253200404]

80 Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernández-Suero JE, Balish E, Hammer RE. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. *J Exp Med* 1994; 180: 2359-2364 [PMID: 7964599]

81 Salmin M, Jalkanen S. Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules. *J Immunol* 2001; 166: 4650-4657 [PMID: 11254724]

82 Kamada N, Seo SI, Chen GY, Núñez G. Role of the gut microbiota in immunity and inflammatory disease. *Nat Rev Immunol* 2013; 13: 321-335 [PMID: 23618829 DOI: 10.1038/nri3430]

83 Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D’Haens G, D’Hoore A, Mantzaris G, Novacek G, Oresland T, Reinsch W, Sans M, Stange E, Vermeire S, Travis S, Van Asche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. *J Crohns Colitis* 2012; 6: 991-1030 [PMID: 23040451 DOI: 10.1016/j.crohns.2012.09.002]

84 Hairel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, Sieper J. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. *Ann Rheum Dis* 2007; 66: 419-421 [PMID: 16901959 DOI: 10.1136/ard.2006.054098]

85 van der Heijde D, Sieper J, Maksmyowycz WP, Dougados M, Burgos-Vargas R, Landewé R, Rudwaleit M, Braun J, Assessment of SpondyloArthritis international Society. 2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. *Ann Rheum Dis* 2011; 70: 905-908 [PMID: 21542800 DOI: 10.1136/ard.2011.151563]

86 McDonald JW, Wang Y, Toulis DJ, MacDonald JK, Feagan BG. Methotrexate for induction of remission in refractory Crohn’s disease. *Cochrane Database Syst Rev* 2014; CD003459 [PMID: 25999640 DOI: 10.1002/14651858.CD003459.pub4]

87 Pouillon L, Bossuyt P, Vanderstukken J, Moulin D, Netter P, Danese S, Jousseau JY, Loueille D, Peyrin-Biroulet L. Management of patients with inflammatory bowel disease and spondyloarthropathy. *Expert Rev Clin Pharmacol* 2017; 10: 1363-1374 [PMID: 28879270 DOI: 10.1080/17512433.2017.1363628]

88 Harbord M, Eliakim R, Bettenworth D, Katsanos K, Kopelow U, Kuchartz T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F, European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. *J Crohns Colitis* 2017; 11: 769-784 [PMID: 28513805 DOI: 10.1093/ecto/ccw099]

89 Lim WC, Wang Y, MacDonald JK, Hanauer S. Aminosalicylates for induction of remission or response in Crohn’s disease. *Cochrane Database Syst Rev* 2016; 7: CD008870 [PMID: 27372735 DOI: 10.1002/14651858.CD008870.pub2]

90 van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Seprano A, Regal A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Geler S, van der Horst-Bruinsma I, Imano RD, Jongkees M, Kiltz U, Kivin TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compañ V, Osgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. *Ann Rheum Dis* 2017; 76: 978-991 [PMID: 28087595 DOI: 10.1136/annrheumdis-2016-210770]

91 Sandborn WJ, Hanauer SB, Katz S, SafdI M, Wolf DG, Baer RD, Tremaine WJ, Diehl NN, Kilkoot A, Rupalo G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Asche G. European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 2: Current management. *J Crohns Colitis* 2017; 11: 769-784 [PMID: 28513805 DOI: 10.1093/ecto/ccw099]

92 Kruglov AA, Grivennikov SI, Kuprash DV, Winsauer C, Prepens S, Seleznik GM, Eberl G, Tumanov AV, Nedospasov SA. Nonredundant function of soluble LTα3 produced by innate lymphoid cells in intestinal homeostasis. *Science* 2013; 342: 1243-1246 [PMID: 23618829 DOI: 10.1126/science.1243364]

93 Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Hairel H, Rudwaleit M, Sieper J. Differences in the incidence of flares or new onset of inflammatory bowel disease in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. *Arthritis Rheum* 2007; 57: 639-647 [PMID: 17471540 DOI: 10.1002/art.22669]

94 Fouache D, Martin A, Deris N, Wendling D, Ansermet T, Berthelot JM, Kantele B, Le CR, Bader-Meunier B, Le Dantec P, Toussriot E, Houvenagel É, Goëb V. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series. *Joint Bone Spine* 2012; 79: 457-463 [PMID: 22089934 DOI: 10.1016/j.jbspin.2011.10.001]

95 Freeman HJ. Collitis associated with biological agents. *World J Gastroenterol* 2012; 18: 1871-1874 [PMID: 22563166 DOI: 10.3748/wjg.v18.i16.1871]

96 Harasui B, Kreienbaum M. Emergence of Crohn’s disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action. *Semin Arthritis Rheum* 2009; 39: 176-181 [PMID: 18706681 DOI: 10.1016/j.semarthrit.2009.11.004]

97 O’Toole A, Lucci M, Korzenik J. Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA. *Dig Dis Sci* 2016; 61: 1772-1774 [PMID: 26728477 DOI: 10.1007/s10620-015-4007-2]

98 Sahil H. Therapies in ankylosing spondylitis-from clinical trials to clinical practice. *Rheumatology (Oxford)* 2018; 57: vi23-vi28 [PMID: 30445440 DOI: 10.1093/rheumatology/key152]

99 Baxten D, Østergaard M, Wei JC, Sieper J, Järvinen P, Tam LS, Salvanari C, Kim TH, Solinger A.
Datsenko Y, Pamulapati C, Visvanathan S, Hall DB, Aslamyan S, Scholl P, Padula SJ. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis 2018; 77: 1295-1302 [PMID: 2945918 DOI: 10.1136/annrheumdis-2018-213328]

102 Østgård RD, Sendid B, Jouault T, Poulain D. Secukinumab failure in Crohn's disease: the yeast connection? Gut 2013; 62: 800-801 [PMID: 23223049 DOI: 10.1136/gutjnl-2012-304154]

103 Fobelo Lozano MJ, Serrano Giménez R, Castro Fernández M. Emergence of Inflammatory Bowel Disease During Treatment with Secukinumab. J Crohns Colitis 2018 [PMID: 2974636 DOI: 10.1093/ecto-jcc/jjy063]

104 Schreiber S, Colombel JF, Feagan BG, Reich K, Deodhar AA, McNees IB, Porter B, Das Gupta A, Pricop L, Fox T. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis 2019; 78: 473-479 [PMID: 30674475 DOI: 10.1136/annrheumdis-2018-214277]

105 Tung C, Kakuta S, Shimizu K, Kadoki M, Kamiya T, Shimazu T, Kubo S, Sajio S, Ishigami H, Nakae S, Iwakura Y. Suppression of IL-17F, but not of IL-17A, provides protection against colitis by inducing Treg cells through modification of the intestinal microbiota. Nat Immunol 2018; 19: 755-765 [PMID: 2951298 DOI: 10.1038/s41590-018-0134-y]

106 Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol 2014; 14: 585-600 [PMID: 25145755 DOI: 10.1038/nri3707]

107 Lee JS, Tato CM, Joyce-Shaikh B, Gulen MF, Cayatte C, Chen Y, Blumschein WM, Judo M, Ayanoglu G, Mcclanahan TK, Li X, Cua DJ. Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability. Immunity 2015; 43: 727-738 [PMID: 26431948 DOI: 10.1016/j.immuni.2015.09.003]

108 Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sancho K, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369: 711-721 [PMID: 23964933 DOI: 10.1056/NEJMoa1215730]

109 Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. Inflamm Bowel Dis 2017; 23: 97-106 [PMID: 27930408 DOI: 10.1097/MIB.000000000000079]

110 Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HH, Danese S, Fox I, Milch C, Sancho K, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710 [PMID: 23964932 DOI: 10.1056/NEJMoa1215734]

111 Orlando A, Orlando R, Ciccia F, Renna S, Rizzo A, Cottone M, Macaluso F. Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritides associated with inflammatory bowel disease. Ann Rheum Dis 2017; 76: e31 [PMID: 28909671 DOI: 10.1136/annrheumdis-2016-211011]

112 Tadjiri S, Peyrin-Biroulet L, Serrero M, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poison C, Althegg R, Marteau P, Vayssie T, Boursier A, Nancey S, Laharie D, Allez M, Savoye G, Gilletta C, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Fumery M, Claudepierre P, Bouhnik Y, Amiot A; GETAID OBSERV-IBD study group. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther 2018; 47: 485-493 [PMID: 29250803 DOI: 10.1111/apt.14419]

113 Varkas G, Thevissen K, De Brabander G, Van Praet L, Czul-Gurdian F, Cypers H, De Kock J, Carron P, De Vos M, Hindryckx P, Arroyo C, Leprince A, Lemoine DJ, Khallouf S, Allez M, Savoye G, Gilletta C, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Fumery M, Claudepierre P, Bouhnik Y, Amiot A; GETAID OBSERV-IBD study group. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a case series. Ann Rheum Dis 2017; 76: 878-881 [PMID: 27893974 DOI: 10.1136/annrheumdis-2016-21032]

114 Feagan BG, Sandborn WJ, Colombel JF, Byrne SO, Khalid JM, Kempf C, Geransar P, Bhayat F, Rubin DT. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. J Crohns Colitis 2019; 13: 50-57 [PMID: 30203005 DOI: 10.1093/ecco-jcc/jjy125]

115 Ferguson LR, Han DY, Fraser AG, Huebner C, Lam WJ, Morgan AR, Duan H, Karunasinghe N. Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population. Mutat Res 2010; 670: 108-115 [PMID: 20109474 DOI: 10.1016/j.mrfmmm.2010.01.017]

116 Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Nieczyporski W; Study A3921043 Investigators. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Inflamm Bowel Dis 2018; 24: 1485-1493.e2 [PMID: 24480677 DOI: 10.1093/ibd/iyx130]

117 Sandborn WJ, Feagan B, Panes J, D'Haens G, Colombel J, Zhou Q, Huang B, Enjeosa W, Judo M, Ayanoglu G, Mcclanahan TK, Li X, Cua DJ. Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability. Immunity 2015; 43: 727-738 [PMID: 26431948 DOI: 10.1016/j.immuni.2015.09.003]

118 Fobelo Lozano MJ, Serrano Giménez R, Castro Fernández M. Emergence of Inflammatory Bowel Disease During Treatment with Secukinumab. J Crohns Colitis 2018 [PMID: 2974636 DOI: 10.1093/ecto-jcc/jjy063]

119 Østgård RD, Sendid B, Jouault T, Poulain D. Secukinumab failure in Crohn's disease: the yeast connection? Gut 2013; 62: 800-801 [PMID: 23223049 DOI: 10.1136/gutjnl-2012-304154]

120 van der Heijde D, Deodhar A, Wei JC, Drescher E, Fleisher D, Hendrikx T, Li D, Menon S, Kanik KS. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis 2017; 76: 1340-1347 [PMID: 28130206 DOI: 10.1136/annrheumdis-2016-210322]

121 Koplyov U, Starr M, Watts C, Dionne S, Girardin M, Seidman IG. Detection of Crohn disease in Patients with Spondyloarthropathy: The SPace Capsule Study. J Rheumatol 2018; 45: 498-505 [PMID: 29449505 DOI: 10.3899/jrheum.161216]

122 Ostgård RD, Deleuran BW, Dam MY, Hansen IT, Jurik AG, Glupov H. Faecal calprotectin detects
subclinical bowel inflammation and may predict treatment response in spondyloarthritis. *Scand J Rheumatol* 2018; 47: 48-55 [PMID: 28649913 DOI: 10.1080/03009742.2017.1299216]

123 **Klingberg E**, Carlsten H, Hilme E, Hedberg M, Forsblad-d'Elia H. Calprotectin in ankylosing spondylitis—frequently elevated in feces, but normal in serum. *Scand J Gastroenterol* 2012; 47: 435-444 [PMID: 22292862 DOI: 10.3109/00365521.2011.648953]

124 **Turina MC**, Yeremenko N, Paramarta JE, De Rycke L, Baeten D. Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. *Arthritis Res Ther* 2014; 16: 413 [PMID: 25133077 DOI: 10.1186/s13075-014-0413-4]

125 **van Tubergen A**, Weber U. Diagnosis and classification in spondyloarthritis: identifying a chameleon. *Nat Rev Rheumatol* 2012; 8: 253-261 [PMID: 22450552 DOI: 10.1038/nrrheum.2012.33]
